Abstract 4324: Inhibition of ERK reactivation by FGTI-2734: A strategy to overcome sotorasib resistance in KRAS G12C lung cancer
Aslamuzzaman Kazi, Hitesh Kumar Kantilal Vasiyan, Deblina Ghosh, Dipankar Bandyopadhyay et autres
Abstract Discovery of sotorasib is a major breakthrough for KRAS G12C targeted therapies. However, overall response rates of patients with KRAS G12C lung cancer treated with sotorasib are modest due to resistance mediated by adaptive reactivation of ERK, which requires wild-type (WT) …
us (code pays fourni par la source)
0 citations
Cancer Research